MEETINGS - "Wie werden Medizinprodukte durch die GKV erstattet?" (Germany) September 2006:
This article was originally published in Clinica
The method of reimbursement for medtech products in Germany via the statutory sickness funds is the theme of a BVMed/MedInform day-long meeting on September 21 in Berlin entitled "Wie werden Medizinprodukte durch die GKV erstattet?" The seminar will provide an overview of the healthcare and insurance systems, noting that the latter is "highly complex and intransparent". Chairing the session will be Daniela Piossek and Olaf Winkler, both of BVMed. For more details, and to register, go to: http://www.bvmed.de/events/date/medinform210906.html
You may also be interested in...
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.